The global age-related macular degeneration treatment market size was exhibited at USD 11.28 billion in 2023 and is anticipated to be expanding around USD 22.05 Billion By 2033, growing at a impressive CAGR of 6.93% from 2024 to 2033.
Key Points
- The North America age-related macular degeneration treatment market size reached USD 5.75 billion in 2023 and is expected to expand around USD 11.36 billion by 2033, at a CAGR of 7.04% from 2024 to 2033.
- North America led the market with the largest revenue share of 51% in 2023.
- Asia-Pacific is expected to experience the fastest rate of growth during the forecast period.
- By product, the eylea segment has held a major revenue share of 52% in 2023.
- By product, the Beovu segment is expected to grow with the highest CAGR during the forecast period.
- By disease type, the wet AMD segment has contributed more than 98% of revenue share in 2023.
- By disease type, the dry AMD segment is expected to be the fastest-growing segment during the forecast period.
- By distribution channel, the hospital pharmacy segment has held a biggest revenue share of 52% in 2023.
- By distribution channel, the specialty pharmacy segment is estimated to witness the fastest growth during the forecast period.
Get the Sample Copy of This Report@ https://www.precedenceresearch.com/sample/4462
Market Overview
The Age-related Macular Degeneration (AMD) Treatment Market focuses on medical treatments designed to manage and slow the progression of age-related macular degeneration, a leading cause of vision loss in older adults. AMD primarily affects the macula, the central part of the retina, resulting in a gradual loss of central vision. The market encompasses various treatment modalities, including pharmaceuticals, biologics, and advanced therapies like gene therapy and stem cell therapy. It is a rapidly evolving field driven by continuous research and development efforts to improve patient outcomes and quality of life.
Growth Factors
The growth of the AMD treatment market is fueled by several key factors. An aging global population significantly contributes to the increasing prevalence of AMD, thereby driving the demand for effective treatments. Advancements in medical technology and a better understanding of the pathophysiology of AMD have led to the development of innovative therapies that are more effective and have fewer side effects. Additionally, increased awareness about eye health and the importance of early diagnosis and treatment among the general population further propels market growth.
Age-related Macular Degeneration Treatment Market Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 11.28 Billion |
| Market Size in 2024 | USD 12.06 Billion |
| Market Size by 2033 | USD 22.05 Billion |
| Market Growth Rate | CAGR of 6.93% from 2024 to 2033 |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, Disease Type, Distribution Channel, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Market Dynamics
Drivers
Several drivers are pushing the AMD treatment market forward. The rising incidence of AMD, particularly in developed countries with aging populations, creates a substantial demand for effective treatment options. The introduction of novel therapeutic approaches, such as anti-VEGF (vascular endothelial growth factor) therapies, which have become the standard of care for neovascular (wet) AMD, has revolutionized the treatment landscape. Furthermore, increasing healthcare expenditure and robust investments in research and development by pharmaceutical companies are significant drivers of market expansion.
Opportunities
The AMD treatment market presents numerous opportunities for growth and innovation. The development of personalized medicine approaches, where treatments are tailored to individual genetic profiles, holds promise for more effective management of AMD. Emerging markets, particularly in Asia-Pacific and Latin America, offer significant growth potential due to improving healthcare infrastructure and increasing awareness about AMD. Additionally, advancements in gene therapy and regenerative medicine could provide breakthrough treatments that not only manage but potentially cure AMD, opening up new revenue streams for companies.
Challenges
Despite the promising growth prospects, the AMD treatment market faces several challenges. High treatment costs, particularly for advanced therapies like anti-VEGF injections, can be a barrier to widespread adoption, especially in lower-income regions. Additionally, the chronic nature of AMD necessitates ongoing treatment, which can lead to patient compliance issues and long-term financial burdens. The market also grapples with regulatory hurdles and the need for extensive clinical trials to ensure the safety and efficacy of new treatments, which can delay the introduction of innovative therapies.
Region Insights
Regionally, North America dominates the AMD treatment market due to its well-established healthcare infrastructure, high healthcare spending, and a large aging population. Europe follows closely, benefiting from similar demographic trends and a strong focus on research and development. The Asia-Pacific region is expected to experience the fastest growth, driven by increasing healthcare awareness, improving medical infrastructure, and rising disposable incomes. Latin America and the Middle East & Africa are also poised for growth, albeit at a slower pace, due to ongoing improvements in healthcare access and economic conditions.
Read Also: https://www.businesswebwire.com/us-point-of-care-infectious-disease-testing-market/
Age-related Macular Degeneration Treatment Market Companies
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
- Bausch Health Companies Inc.
- Regeneron Pharmaceuticals Inc.
- Amgen Inc.
- Bayer AG
- Biogen
- Samsung Bioepis
- Abbvie, Inc
Recent Developments
- In October 2023, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Vabysmo for the treatment of Retinal Vein Occlusion (RVO), neovascular or wet age-related macular degeneration, and diabetic macular edema.
- In August 2023, Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had approved EYLEA HD injection for treating patients suffering from wet age-related macular degeneration.
- In August 2023, Astellas Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) had approved IZERVAY injection for geographic atrophy (GA) and age-related macular degeneration (AMD) disease.
- In February 2023, Apellis announced that the U.S. Food and Drug Administration (FDA) had approved SYFOVRE injection for the treatment of geographic atrophy (GA) and age-related macular degeneration (AMD) disease.
Segments Covered in the Report
By Product
- Eylea
- Lucentis
- Beovu
- Others
By Disease Type
- Dry AMD
- Wet AMD
By Distribution Channel
- Hospital Pharmacy
- Specialty Pharmacy
- Online Pharmacy
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.dailystatsnews.com/